YFY Biotech Management Company
YFY Biotech Management Company, established in 2003, serves as the corporate venture capital arm of Yuen Foong Yu Paper Manufacturing Company in Taipei, Taiwan. The company concentrates on the bio-pharmaceutical, diagnostics, medical device, and healthcare technology sectors. YFY Biotech specializes in various investment stages, including incubation, seed and startup funding, as well as early and later-stage investments, alongside growth and buyout opportunities. Its strategic focus enables it to support innovative companies and technologies within the life sciences field, contributing to advancements in healthcare solutions.
Past deals in Taiwan
TaiGen Biotechnology
Series C in 2009
TaiGen Biotechnology Co., Ltd. is a pharmaceutical company headquartered in Taipei, Taiwan, with additional operations in Beijing, China, and the United States. Founded in 2001, the company specializes in the discovery, development, and commercialization of innovative therapeutics targeting infectious diseases, cancer, and complications related to diabetes. Its product portfolio includes Nemonoxacina, an anti-infection drug effective against drug-resistant pathogens; Taigexyn, a non-fluorinated quinolone antibiotic; and TG-1000, which treats influenza A and B. Additionally, TaiGen develops stem cell mobilizers for therapeutic applications in leukemia and offers a range of inhibitors for hepatitis C, as well as treatments for various bacterial infections. The company's focus on addressing unmet medical needs positions it as a significant player in the pharmaceutical industry.
TaiGen Biotechnology
Series B in 2004
TaiGen Biotechnology Co., Ltd. is a pharmaceutical company headquartered in Taipei, Taiwan, with additional operations in Beijing, China, and the United States. Founded in 2001, the company specializes in the discovery, development, and commercialization of innovative therapeutics targeting infectious diseases, cancer, and complications related to diabetes. Its product portfolio includes Nemonoxacina, an anti-infection drug effective against drug-resistant pathogens; Taigexyn, a non-fluorinated quinolone antibiotic; and TG-1000, which treats influenza A and B. Additionally, TaiGen develops stem cell mobilizers for therapeutic applications in leukemia and offers a range of inhibitors for hepatitis C, as well as treatments for various bacterial infections. The company's focus on addressing unmet medical needs positions it as a significant player in the pharmaceutical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.